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Abstract Analysis of volatile organic compounds (VOCs)
emanating from human exhaled breath can provide deep
insight into the status of various biochemical processes in
the human body. VOCs can serve as potential biomarkers
of physiological and pathophysiological conditions related
to several diseases. Breath VOC analysis, a noninvasive
and quick biomonitoring approach, also has potential for
the early detection and progress monitoring of several
diseases. This paper gives an overview of the major VOCs
present in human exhaled breath, possible biochemical
pathways of breath VOC generation, diagnostic importance
of their analysis, and analytical techniques used in the
breath test. Breath analysis relating to diabetes mellitus and
its characteristic breath biomarkers is focused on. Finally,
some challenges and limitations of the breath test are
discussed.
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1 Introduction
Bioinformation obtained from volatile organic compounds
(VOCs) in the exhaled breath of humans can aid the early
diagnosis of several diseases and can be used to decide
relevant medical therapies. The analysis of exhaled breath
and associated VOCs has gained a considerable scientific,
clinical, and research attention due to its potential in
enabling the noninvasive observation of the biochemical
processes of the human body [1–3]. The first initiatives of
breath analysis for determining the physiological state of
humans originated during the time of Hippocrates (460-370
BC), when the ancient Greek physicians realized that some
diseases could be diagnosed from the characteristic odor of
patients’ breath and knew that the human breath might
provide sound information on health conditions [1–6]. In
the period 1782–1783, Lavoisier for the first time analyzed
the breath CO2 of Guinea pigs and showed that the gas is a
product of combustion in the body [1, 5]. Practically, it is
not difficult for a skilled technician to recognize the
characteristic ‘fruity smell’ of acetone, ‘musty and fishy
smell’, ‘urine-like smell’, and ‘putrid smell’ in the breath
of patients with diabetes, advanced liver disease, kidney
failure, and lung abscess, respectively [1]. The analysis of
VOCs present in exhaled breath can thus provide valuable
information about the subjects’ physiological and patho-
physiological conditions. Such compounds can be useful
indicators and potential biomarkers of various diseases and
metabolic activities, facilitating disease diagnosis. It should
be noted that biological monitoring is generally based on
the analysis of blood. However, this involves an invasive
and time-consuming technique, which is often unaccept-
able concerning patient care system. This invasive tech-
nique also needs skilled medical staff. Breath analysis is
thus a very attractive alternative as it is a noninvasive and
quick method that allows repeated sampling [1, 7].
A plethora of studies have reported the significance of
analyzing VOCs in human breath [8–10]. In 1938, the
‘drunkometer’ was introduced as a roadside test of breath-
alcohol concentration [7, 11]. In the 1970s, Pauling et al.
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[12] used gas chromatography (GC) to detect more than
200 VOCs in human breath. Their contribution gave new
insight into the human body and directed research in the
analysis of VOCs for clinical diagnosis and therapeutic
monitoring [2, 13, 14]. Since then, many studies have been
carried out in this field. In 1997, Phillips [15] estimated
1259 VOCs from 20 normal healthy subjects using gas
chromatography–mass spectrometry (GC/MS). In 1999,
using GC/MS, Phillips et al. described 3481 VOCs in the
breath gas of healthy controls, with an average number of
about 200 VOCs detectable in an individual’ breath gas
[16]. Recently, 1765 VOCs of healthy humans have been
published [5, 17].
Compounds in exhaled breath gas are generally classi-
fied as [3]:
1. Inorganic compounds, such as nitric oxide, oxygen,
and carbon dioxide [18].
2. Exhaled breath condensate, which includes cytokines,
hydrogen peroxide, isoprostanes, and leukotrienes
[17].
3. VOCs, such as ethane, pentane, aldehydes, and
isoprene [2, 18, 19].
In the context of the diagnosis of human diseases, a
number of volatile biomarkers in exhaled breath have been
reported [17, 18, 20–24]. It is essential to determine such
biomarkers in order to monitor metabolic or any pathologic
processes in the body. Expired breath VOCs that are
commonly used for diagnostic purposes include oxygen-
containing compounds (e.g., ethanol, methanol, 2-propa-
nol, acetone, and acetaldehyde), hydrocarbons (e.g.,
ethane, pentane, and isoprene), sulfur-containing com-
pounds (e.g., methyl mercaptanes, ethyl mercaptanes, and
dimethyl sulfide), and nitrogen-containing substances (e.g.,
dimethylamine, trimethylamine, and ammonia) [2]. Ace-
tone, isoprene, ethanol, methanol, other alcohols and
alkanes have been reported to be the major identified VOCs
[3, 25]. A few of the above-mentioned types of breath VOC
along with their possible biochemical pathways in the
human body are discussed below.
2 Origin and Biochemical Pathways of Major
VOCs in Human Exhaled Breath
2.1 Oxygen-Containing Compounds
Acetone is one of the major abundant VOCs in human
breath [2, 26]. It should be emphasized here that acetone
production in animals is believed to originate from two
pathways: the decarboxylation of acetoacetate [2, 26–29]
and the dehydrogenation of isopropanol or 2-propanol
[27–30]. The first pathway, the major source of acetone
production in mammals, arises from either lipolysis (lipid
peroxidation) or amino acid degradation [2, 26–29]. Ace-
toacetate decarboxylation may occur both in an enzyme-
catalyzed manner and non-enzymatically. Studies on vari-
ous rat tissues (e.g., kidney, liver, brain, placenta, and
plasma) and human plasma [27, 29] have established the
presence of enzymatic activity. Figure 1 illustrates the
generation of acetone generated by hepatocytes via the
decarboxylation of excess acetyl–coenzyme A (acetyl–
CoA). The second metabolic pathway includes the dehy-
drogenation of 2-propanol (by liver alcohol dehydrogenase,
ADH) to acetone. This acetone is released mostly via urine
and exhaled breath from the body. Acetone may also be
further metabolized to acetate, formate, and carbon dioxide
[30]. Acetone, a natural metabolic intermediate of lipoly-
sis, is as a potential biomarker for monitoring the ketotic
state of diabetic and fasting individuals, assessing fat loss,
and measuring glucose levels [26].
In the human body, the origins of ethanol and methanol
are not well understood [31–33]. However, these VOCs are
believed to originate from microbial fermentation of the
carbohydrates in the gastro-intestinal tract [31, 34–36].
Intestinal bacterial flora is regarded as an important source
of breath ethanol [37] and methanol [38]. It has been
proposed that methanol derives from S-adenosylmethion-
ine in the pituitary or from the breakdown of ethanol by
intestinal flora [32]. Usually, the breath ethanol concen-
trations in human subjects are much lower than those found
in human breath after the intake of alcohol. It has also been
postulated that an enzyme-mediated reduction of acetone
forms 2-propanol in the body, implying that its
Fig. 1 Generation pathway of acetone in liver by hepatocytes [2]
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concentration in humans remain lower than acetone con-
centrations [38].
Researchers also claim ethanol and methanol to be
mostly of microbial or exogenous origin [35]. Sources of
exogenous methanol in the healthy human body include
fruits, vegetables, and alcoholic beverages [35]. Methanol
levels in breath may be influenced by intake of fruit-
derived pectin [36]. In a recent study on C57BL/6J mice
revealed that methanol source strengths are barely affected
by body mass. Rather, they are influenced by the diet
matrix and a low-fat diet [36]. Regardless of the source,
low levels of methanol are always maintained by the
human physiological system [35].
Acetaldehyde originates as the first product, primarily in
the liver during the metabolism of ethanol. Here, ethanol is
oxidized by ADH. The enzyme aldehyde dehydrogenase
converts the produced acetaldehyde to acetate [39]. Breath




The major fractions of exhaled ethane and pentane are of
systemic origin [2, 40]. These compounds are thought to
originate from lipid peroxidation, a chain reaction that
starts when an allylic hydrogen atom is eliminated by
reactive oxygen species (ROS). The resulting radical is
conjugated, peroxidized by oxygen, and undergoes further
chemical reactions. The generation of ROS is described as
the destructive aspect of oxidative stress [41]. In oxidative
stress, cells are damaged as a result of a chemical reaction
with oxidative agents (e.g., the superoxide anion or
hydroxyl radical) [6, 42]. ROS bear free radicals and per-
oxides. These species may undergo further chemical
changes and turn into more aggressive radical agents that
can potentialy cause extensive cellular damage.
Saturated hydrocarbons, e.g., ethane and pentane, are
produced from x3 (e.g., linolenic acid) and x6 fatty acids
(e.g., linoleic and arachidonic acid), respectively (Fig. 2).
These fatty acids have been described as the fundamental
components of cell membranes [2, 6, 40, 43–45]. In vitro
studies reveal that ethane and pentane originate when cell
cultures are exposed to ROS. These aliphatic hydrocar-
bons are considered as in vitro and in vivo biomarkers of
lipid peroxidation due to the close correlations between
their exhalation and clinical conditions with high perox-
idative activities, as suggested by various experimenta-
tions [46]. The levels of exhaled pentane and ethane are
closely linked to other lipid peroxidation markers such as
thiobarbituric acid reactive substances (e.g., malondi-
aldehyde) [33]. Protein oxidation and colonic bacterial
metabolism, despite being other important sources of
hydrocarbons in the human body, have less potential in a
hydrocarbon breath test for ethane and pentane [43].
Methylated hydrocarbons are also considered lipid per-
oxidation markers [2, 47, 48].
Several diseases, e.g., lung cancer [49], HIV [50], and
inflammatory bowel disease [51], are also influenced by
oxidative stress induced by ROS generation. Further study
is required to conceptualize the biochemical process of the
generation and physiological interpretation of these com-
pounds [2, 52]. Such hydrocarbons are stable end products
of lipid peroxidation [2, 6, 45]. They are less soluble in
blood and are hence released into the breath quickly after
their formation in tissues. Thus, exhaled ethane and
n-pentane concentrations have potential in the monitoring
of oxidative stress in the body [45, 53, 54].
Elevated levels of ethane have been reported for patients
with asthma, chronic obstructive pulmonary diseases
(COPD), and cystic fibrosis [55–57]. Pentane has also been
observed at increased levels in asthma patients [40, 58].
The concentrations of ethane and pentane are flow-depen-
dent in asthmatic subjects [40].
2.2.2 Unsaturated Hydrocarbons
Isoprene (2-methyl-1,3-butadiene) is the major hydrocar-
bon found in human exhaled breath [59, 60]. It is thought to
be formed following the mevalonic acid (MVA) pathway
(Fig. 3) of cholesterol biosynthesis [2, 40, 61–64]. The
formation of mevalonate from acetic acid is a crucial
chemical reaction in the cholesterol biosynthesis. The
compound 3-hydroxy-3-methyl-glutaryl coenzyme A
(HMGCoA) catalyzes the rate-limiting step of sterol syn-
thesis. Next, mevalonate is converted in the cytosol to
isopentenyl pyrophosphate, followed by isomerization to
dimethylallyl pyrophosphate (DMPP) [65]. After passing
through the formation of intermediate carbonium ion,
DMPP is rapidly converted to isoprene via an acid-cat-
alyzed elimination reaction [2, 66]. It has been reported
that breath isoprene levels can be decreased in humans by
administration of HMGCoA reductase inhibitors, which
block the enzyme responsible for the production of MVA
during cholesterol biosynthesis [2].
The 1-deoxy-D-xylulose-4-phosphate/2-C-methylery-
thritol 5-phosphate (DOXP/MEP) pathway is regarded as
another pathway of isoprene generation in plants and most
bacteria. In plants and bacteria, the enzyme isoprene syn-
thase converts DMPP into isoprene [63]. The MVA path-
way is mainly present in higher eukaryotes [67]. A small
fraction of exhaled isoprene may be of bacterial origin
[68]. However, the exact origins have not been found
[66, 69]; further study on the origin of isoprene in the
human body is needed.
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Isoprene levels have been found to be decreased in
patients with acute respiratory distress syndrome [70],
cystic fibrosis [71], and asthma [40]. The concentration of
isoprene in breath appears to be age-dependent. Nelson
et al. [72] found that children show significantly low con-
centrations of breath isoprene. It has also been reported that
isoprene levels in breath are increased during physical
activity. Isoprene, stored in muscles, gets released during
muscle contraction (i.e., it is exercise-induced) [64, 73].
The change in breath isoprene concentration can also be
contributed to the alteration of diffusion capabilities of
peripheral tissue [64]. Increased production of breath iso-
prene has been observed in human subjects and animals
with chronic kidney disease (CKD). In CKD animals,
elevation of isoprene levels is associated with a significant
increase in serum cholesterol level [62]. Breath isoprene
levels are also altered by physiological and pathophysio-
logical states (including hemodialysis, general anesthesia,
liver disease, and cancer [74, 75]).
2.3 Sulfur-Containing Compounds
It has been reported that sulfur-containing compounds in
the human body originate from the incomplete metabolism
of methionine via the transamination pathway [2]. Such
compounds, e.g., dimethyl sulfide, dimethyldisulfide, and
ethyl mercaptane, manifest as a distinctive odor in cirrhotic
patients’ breath [76–78]. Sulfur compounds are suggested
as major markers of liver failure [2]. The breath of patients
with hepatocellular failure may have a sweet, musty, or
Fig. 2 Possible reactions and
their products in free-radical-
mediated lipid peroxidation [2]
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slightly fecal aroma, termed fetor hepaticus, which is
mostly attributed to sulfur compounds. Dimethyl sulfide is
regarded as an important metabolite for fetor hepaticus
[79]. Impairment of liver function increases the level of
these compounds, which have a characteristic smell, such
as that of rotten cabbage [77, 80]. Bacteria and fungi
related to lung infection (e.g., Haemophilus influenza,
Streptococcus pneumoniae) also generate dimethyl sulfide
[81]. Normally, human blood and breath shows very low
(few parts per billion) concentrations of sulfur-containing
compounds [5].
2.4 Nitrogen-Containing Compounds
Identification and quantification of amines in human breath
has been reported since 1977. Patients with chronic renal
failure have been reported to exhibit characteristic uremic
breath odor, which is termed ‘ammoniacal’, ‘fishy’, or
‘fetid’. Using GC, the presence of nitrogen-containing
compounds (e.g., dimethylamine and trimethylamine at
elevated concentration levels) contributing to the odor of
uremic breath was established [82].
Ammonia is the major nitrogen-containing volatile
biomarker. It originates in the body as a breakdown product
of proteins. A substantial amount of these proteins comes
from the bacterial degradation of proteins in the intestine.
In the liver, ammonia is converted to urea and released in
urine. Some of the ammonia is also released through the
breath and the skin. Increased levels of ammonia have been
observed in the blood when the liver fails to convert
ammonia to urea. This may happen in subjects with cir-
rhosis or severe hepatitis [83].
Breath ammonia concentration is also influenced by
cigarette smoking [84]. A relatively high concentration
range [245–2935 ppb] of breath ammonia has been repor-
ted in normal healthy humans [83]. Such elevated levels
may also be related to bacterial production in the oral
cavity [5].
In the context of disease diagnosis using breath VOCs,
several factors should be taken into consideration. The
biology underlying both health and pathology is a com-
plicated, non-linear, and dynamic process [85]. Human
breath includes a complex composition. Food products,
inhaled air composition, and volatiles that originate from
normal and disease-related metabolic processes influence
breath VOC content [23, 28, 86, 87]. For example, genomic
and structural changes in the lung epithelium can alter the
VOC concentration developed in normal physiological
processes [88, 89]. Environmental sources [e.g., diet and
inhaled (polluted) air] contribute a major part of exhaled
breath VOCs [90]. For a breath test for disease identifica-
tion, VOCs from systemic origin should be emphasized and
exogenous VOCs should be excluded. However, exoge-
nous breath VOCs may undergo physiochemical changes
before exhalation [91]. Bacteria present in the lungs, gut,
and oral cavity in animals and humans are potential VOC
producers [92, 93]. Thus, VOCs of microbial origin in the
human body cannot be overlooked and may be utilized in
disease diagnosis.
A large number of VOCs have been found in human
breath. Although many of them have been reported to be
biomarkers of several diseases, their exact physiological
interpretation, including their biochemical status both in
diseased and healthy conditions of the subjects, needs
further study. It should be noted that the concentration
ranges of breath VOCs for diseased persons and normal
healthy subjects are not similar. For example, some
exhaled breath VOCs and their concentration ranges in
normal healthy subjects and lung cancer patients are given
in Table 1.
3 Underlying Principle in Exhaled Breath
Analysis
The underlying principle of breath analysis is based on the
relatively rapid equilibrium between alveolar air and pul-
monary capillary blood [94]. Following Henry’s law, it can
be stated that the quantity of a given substance released
through the lungs varies in proportion to its vapor pressure
[95]. Due to the rapid gas exchange at the blood-gas
interface in the lungs, the gaseous compounds present in
expired breath are directly proportional to their blood
Fig. 3 Metabolic pathway of cholesterol synthesis and isoprene
generation [61]
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concentrations. However, no specialized transport system
has been reported for the excretion of lethal gaseous sub-
stances by the lungs; such substances seem to be eliminated
by the process of simple diffusion [94, 95]. Also, the
elimination of gaseous substances is inversely proportional
to their absorption by the lungs [95]. This mechanism holds
true for any gas or vapor with no special affinity for certain
blood components. During inhalation, gas molecules dif-
fuse from the alveolar space into the blood and become
dissolved. The uptake of gas molecules by tissues utilizes a
simple physical dissolution process, facilitating the
partition of these molecules between the air and blood
during absorption and between blood and other tissues
during distribution.
Any chemical substance in the alveoli stays there suf-
ficiently long to reach a state of equilibrium with the blood.
However, due to continuous contact of the inspired with
blood, the state of equilibrium occurs rapidly. The ratio of
the concentration of the chemical in the blood to that in the
gas phase is constant at this equilibrium, termed the blood-
gas partition coefficient (K), and is unique for every gas
[95].
Table 1 Various breath VOCs and their concentrations in healthy normal subjects and lung cancer patients
Sl. no. VOC Concentration (range/median/mean)a values (ppb)
Normal healthy subjects Lung cancer patients
1 Isoprene [3, 10, 15, 16, 208] 12.71 [209] to 227 [210] 80–225.6 [208]
2 Acetone [3, 15, 16, 199, 211–213] 44 [199] to 2744 [83] 150–870 [131]
3 2-Pentanone [15, 199] 1.80–4.11 [199] 3.25–8.77 [199]
4 Ethylbenzene [3, 15, 16, 199, 208, 213, 214] 0.28 [208] to 18.38 [199] 1.45–3.16 [199]
5 Xylenes 0.54–1.43 [208] 1.1–2.76 [208]
6 Toluene [199, 208, 211–213] 1.45–37.21 [199] –
7 Ethane [15, 215] 0.51–1.02 (non-smokers) [216] –
8 Pentane 6.84–14.36 [199] 1.73 [199] to 28.3 [208]
9 Propane [212–214] 3.71–19.98 [212] –
10 Ethanol [2, 15, 16, 211–213, 215] 27 [217] to 216.1 [218] 64–2160 [131]
11 Methanol [2, 16, 213] 33.05–216.1 [218] 63–110 [131]
12 Undecane [15, 16] 0–4.83 [219] –
13 Nonanal [15, 16, 220, 221] 0.18 [220] to 2.44 [221] 0.8 [220] to 12.61 [221]
14 Benzene [3, 15, 16, 199, 208, 213, 215] 0.7 [208] to 14.97 [199] 1.29–3.82 [199]
15 Heptane [3, 15, 16, 208, 215] 0.13–0.39 [208] 0.04–0.86 [208]
16 2-Methylpentane [15, 16, 199, 208, 213, 215] 0.08 [208] to 10.80 [199] 0.93 [199] to 7.6 [208]
17 Butanal [199, 211, 215, 220, 221] 0.18 [220] to 72.2 [211] 0.48 [220] to 131.4 [211]
18 Acetonitrile [199, 211–213] 5.99–28.98 [199] 10.96–23.60 [199]
19 Butane [16, 211–213] 3.6–14.8 [211] 3.3–9.2 [211]
20 2-Propanol (isopropanol) [15, 16, 199, 213] 3.21 [199] to 94.1 [13] 84.2–340.7 [211]
21 3-Methylpentane [15, 16, 199, 212, 213] 1.05–8.76 [199] 0.94–8.87 [199]
22 Hexane [15, 16, 199, 211–213] 0.29–12.86 [212] 1.44–1.88 [199]
23 Styrene [16, 208, 213] 0.14–0.55 [208] 0.22–0.95 [208]
24 Octane [15, 16, 208, 213] 0.1–1.29 [208] 0.57–2.87 [208]
25 Decane [15, 16, 208, 213] 0.36–10.3 [208] 7.1–33.6 [208]
26 1,2,4-Trimethylbenzene [15, 16, 208] 0.12–0.28 [208] 0.24–0.56 [208]
27 Hexanal [15, 220] 0.18–0.35 [220] 0.68–1.47 [220]
28 Pentanal [15, 220] 0.11–0.37 [220] 0.32–1.08 [220]
29 Methanethiol [212] 1.83–2.87 [212] –
30 Dimethyl sulfide [211, 212] 6.9–7.9 [211] 0–6.9 [211]
31 2-Methyl-1,3-butadiene 96.4 (median) [211] 132.7 (median) [211]
32 1-Butanol [222] 0.75 (median) [222] –
a Data in other units (e.g., nmol/l, lg/l, etc.) are converted to equivalent ppb unit, considering breath temperature at 310 K and following the
conversation formula applied in Ref. [212]
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Due to the simple mechanism described above, the
VOCs in breath can be an excellent indicator of the levels
of these compounds in blood [94]. However, the biomon-
itoring and interpretation of VOCs in breath also requires
special attention to factors that can influence pulmonary
excretion. Such factors include metabolism, breathing
technique, diffusion–adsorption–desorption, ventilation–
perfusion, temperature, blood composition, and time [96].
3.1 Significance of VOC Analysis in Human Breath
Analysis and Applications
Regarding clinical prospects, breath samples have appli-
cation in the following major areas:
1. Clinical diagnosis Here, the aim is to analyze VOCs
produced in the organism and released through expired
or exhaled breath.
2. Exposure analysis Here, the aim is to obtain quick and
accurate information concerning the levels of highly
toxic exogenous VOCs that reach the blood stream.
Clinical diagnosis, being a noninvasive and quick
approach, has achieved a scientific research interest in the
field of medical science and technology [1, 2, 97–100].
Exposure assessment is mainly used for detecting noxious
substances in indoor environments, which is outside of the
scope of the present review.
The determination of VOCs in breath samples can pro-
vide clinically significant information for the diagnosis of
diseases and biochemical processes involved. Elevated
levels of ethane and pentane have been reported as markers
of oxidative stress in subjects with heart transplant rejec-
tion [1, 2, 101], breast cancer, bronchial asthma [1, 101],
asthma, COPD, obstructive sleep apnea, acute respiratory
distress syndrome (ARDS), and mental and physical stress
[2, 101]. Methylated alkanes have also been proposed as
markers of oxidative stress [1, 101]. Increased concentra-
tions of exhaled n-alkanes have been observed following
reperfusion of cardiopulmonary bypass [102] and in sub-
jects with abdominal ischemia [103], ischemic liver [104],
myocardial infarction [105], and ischemic heart disease
[106]. Sepsis, or systemic inflammatory response syn-
drome, patients exhale significantly more pentane com-
pared to that exhaled by healthy subjects [70]. Although
few studies have found propane and butane (resulting from
protein oxidation and fecal flora) to be biomarkers of lipid
peroxidation [2], a recent study [42] claimed that patients
with schizophrenia and bipolar disorder exhibit signifi-
cantly increased levels of breath ethane and butane.
Reduced isoprene levels have been found in patients with
chronic heart failure [107] and ARDS [108]. Clinical
studies demonstrated that isoprene may serve as a marker
of cellular damage and repair. Increased concentration of
isoprene has been reported in breath after smoking [109].
Several studies found elevated isoprene breath concentra-
tions during and after hemodialysis [110]. Relatively
higher concentrations of sulfur-containing compounds have
been reported in liver transplant patients [111] and patients
with liver disease [112]. The expired breath of cirrhotic
patients includes ethyl mercaptane, dimethyl sulfide, or
dimethyl disulfide, which are sulfur-containing com-
pounds. Impairment of liver function also increases the
level of sulfur-containing compounds [2, 101]. Heli-
cobacter (H.) pylori infection can be detected using the
urea breath test [1, 101]. Elevated levels of acetone in the
expired breath of diabetes mellitus patients have been
reported [2, 113]. The VOCs of cystic fibrosis and breast,
colon, and prostate cancer patients have been detected in
some recent studies [3, 101]. It has also been reported that a
combination of more than 20 breath VOCs, predominantly
alkanes, alkane derivatives, o-toluidine, aniline, and ben-
zene derivatives, along with altered lipid peroxidation
activity [1, 101], are able to distinguish patients with lung
cancer at a probability level of about 70 %. Elevated levels
of ammonia have been observed in the expired breath of
patients with uremia, end stage renal failure [83, 84], acute
liver failure, and hepatic encephalopathy [114–116].
Breath ammonia is also influenced by infection by H. py-
lori [114], which disturbs cerebral function [115] and
produces symptoms of Alzheimer’s disease [116].
The breath test was applied by Humphreys et al. [117] to
the diagnosis of pneumonia associated with invasive
mechanical ventilation. Similar studies on pneumonia
diagnosis have been carried out by Hockstein et al. [118]
and Hanson et al. [119] with satisfactory outcomes. In a
study on 60 asthma patients (21 fixed asthma patients and
39 classic asthma patients) and 40 COPD patients, Fens
et al. [120] discriminated fixed asthma patients from COPD
patients and classic asthma patients, respectively.
Remarkable results were also reported by Fens et al. [121]
when they compared the exhaled VOCs from 20 asthma
patients, 30 COPD patients, 20 non-smoker controls, and
20 smoker controls. Another research group [122] analyzed
the exhaled air from 10 controls and 18 COPD patients. All
the COPD patients and 8 of the 10 controls were reported
to be correctly identified. Dragonieri et al. [123] discrimi-
nated 10 asthma patients from 10 healthy subjects. Similar
results were obtained by Montuschi et al. [124], who
recruited 27 asthma patients and 24 healthy subjects. The
breath test has also been utilized to diagnose other respi-
ratory diseases, including tuberculosis [125–127] and
apnea [128–130]. Machado et al. [131] compared the
exhaled breath VOCs of 14 lung cancer patients with 54
control patients. In another study, Dragonieri et al. [132]
compared the VOCs present in the breaths of 10 lung
cancer patients with those of 10 healthy controls and 10
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COPD patients, and found significant differences between
the groups. Natale et al. [133] and Chen et al. [134] also
performed breath tests to characterize lung cancer patients.
From the above discussion, it is undeniable that the
analysis of VOCs in exhaled breath has potential for clin-
ical diagnosis. However, the breath test has some short-
comings. The advantages and limitations of the breath test
are listed in Table 2.
4 Analytical Techniques Applied in Exhaled
Breath VOC Analysis
Several techniques have been tailored and employed to
monitor and analyze the VOCs present in human exhaled
breath. Technologies used in the breath test are described
below.
It should be noted that there are some potential obstacles
in breath gas analysis. These include low concentrations of
exhaled breath VOCs, lack of proper sampling and mea-
suring techniques, and high humidity of breath gas [10].
The majority of breath VOCs have nanomolar (10-9) and
picomolar (10-12) concentration ranges and require highly
sensitive devices and sophisticated analytical methods for
their proper identification [13]. Modern sampling and
analytical methods have solved these problems to some
extent.
The analysis of VOCs in exhaled breath requires some
advanced technology that may pacify the analysis process
and provide reliable interpretation of the obtained data. In
this regard, incorporating sensors and sensor arrays might
be useful in the analysis of expired breath VOCs of dia-
betes patients.
4.1 Gas Chromatography and Gas
Chromatography–Mass Spectrometry
Commonly used methods for the analysis of exhaled breath
VOCs are GC, GC–MS, and GC with tandem MS (GC–
MS2) [4, 7, 61, 98]. In practice, GC/MS systems are often
associated with other methods, e.g., solid-phase extraction
(SPE) and solid-phase microextraction (SPME), for the
analysis of breath VOCs [1]. In breath analysis, GC–MS
employs the electron impact ionization technique. The
unique fragmentation pattern of each analyte molecule is
used for its identification, which is done using chromato-
graphic retention data and mass spectral data using spectral
libraries [98]. GC–MS has high reproducibility, high sen-
sitivity, and robustness [135] and conveys potential infor-
mation of biological mechanisms relevant to respective
VOCs [136, 137].
Combined with a preconcentration system, these meth-
ods can be effectively applied to the off-line collection,
separation, and identification of the majority of compounds
(e.g., aliphatics, alcohols, aldehydes, ketones, amines, and
halogenated compounds) in human breath [4, 7, 98]. GC
and GC–MS have numerous applications in clinical studies
[2, 138]. These systems are sufficiently sensitive to quan-
tify breath gases of very low concentration (parts per bil-
lion/ppb/ppbv—parts per trillion/ppt/pptv) levels
[139, 140].
However, despite their high sensitivity, GC–MS and
related methods have poor portability and are time-con-
suming, costly, difficult to handle, and not suited for real-
time and repeated measurements [10]. Therefore, GC–MS
is used especially when the aim is to identify VOCs in
pathophysiological discovery, even though it can also be
clinically incorporated in larger hospitals when logistics
allow samples to be directly analyzed.
4.2 Proton-Transfer Reaction-Mass Spectrometry
Compared to GC–MS, proton-transfer reaction-mass
spectrometry (PTR-MS) is more sensitive in detecting
VOC concentrations, down to ppt [13] and ppb levels
[7, 61, 141], quickly and accurately and does not require
the time-consuming preconcentration step [13]. In PTR-
MS, analytes are characterized as per their mass-to-charge
(m/z) ratio only. PTR-MS includes an ion source and a drift
tube (ion-transfer region) coupled to an MS detector. H3O
?
ions generated in the ion source region are mixed with an
air sample continuously flowing at the top of the drift tube
and proton transfer takes place as the gas sample passes
through the drift tube [142].
PTR-MS has been used for monitoring anesthetic agents
[143], breath profiling [144], and studying the effects of
Table 2 Advantages and
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hemodialysis [145]. This technique is also suited for online
and multiple measurements. However, PTR-MS systems
cannot differentiate between substances that have the same
molecular mass [13]. Chemical identification of the ana-
lytes thus cannot be performed using this technique. For
this purpose, other techniques should be used [7, 10].
4.3 Selected Ion Flow Tube-Mass Spectrometry
Similar to PTR-MS, selected ion flow tube-mass spec-
trometry (SIFT-MS) shows quick performance in quanti-
fying exhaled breath analytes [4, 7, 61]. SIFT-MS employs
a chemical ionization technique using positive precursor
ions (H3O
?, NO?, or O2
?) generated in an ion source. The
ion–molecule reactions in SIFT-MS generate characteristic
product ions corresponding to each trace gas species pre-
sent in the sample. These product ions are mass-sorted and
counted by a downstream detection system. SIFT-MS has
been applied to polar substances (e.g., acetone, ammonia,
acetaldehyde, and alcohols) and unsaturated hydrocarbons
(e.g., isoprene) [98].
SIFT-MS is a potential real-time quantification tool for
several breath gases [4, 61, 146–148]. It can detect several
VOCs with concentrations at ppt/pptv and ppb/ppbv levels
[7, 61, 98]. SIFT-MS outperforms GC–MS in terms of the
identification and analysis of small molecules [149]. For a
specified mass range, a large number of target compounds
can be detected and monitored simultaneously.
4.4 Sensor Arrays and Electronic Noses
Sensor technology has been utilized in several clinical tests
(e.g., blood gas analysis) for many years [98]. Sensor
systems are characterized by their high throughput, ease of
use, and affordability [150]. With the aid of modern fab-
rication techniques, sensor arrays find their notable imple-
mentations in optimizing the conditions for clinical
applications. One of the major sensor-based techniques in
the clinical domain is the electronic nose (e-nose), which
incorporates a series of non-selective gas sensors and a
pattern-recognition algorithm [4, 150, 151]. The pattern of
volatile compounds may represent not only an infecting
organism or a disease state but also the metabolism of the
host response, as well as other associated conditions
[97, 152].
An e-nose, resembling the human (or animal) nose, can
recognize the ‘smell-print’ to which it is trained [7, 61].
Utilizing nanosensor arrays, an e-nose detects patterns in
complex mixtures of exhaled breath VOCs. Such patterns
may serve as potential indicators of certain disease condi-
tions [7, 97, 121, 131, 152] and can pacify the clinical
diagnosis process. E-noses have been used for detecting
pathogens present in bacterial cultures [1, 153] and
determining halitosis [1], uremia [154], renal disease, air-
way inflammation [1, 155], cancer [1, 3, 13, 132, 156],
malignant pleural mesothelioma [157], and pulmonary
diseases [1, 120, 121, 127, 132].
4.5 Ion-Mobility Spectrometry
Ion-mobility spectrometry (IMS) is a fast technique that
can detect volatile compounds of very low concentrations
(ppm–ppb) without any preconcentration [7, 98]. It is based
on estimating the time taken for an ion to travel through a
drift tube. Variations in the humidity of an exhaled breath
sample may influence the ion-drift time [7]. IMS can
separate and identify different substances under ambient air
conditions. IMS can be coupled with GC [158] or MS [159]
for unequivocal identification of substances.
IMS measures disease-specific combinations of VOCs,
and characterizes the mixture using a pattern recognition
algorithm to aid clinical diagnosis. Wide application of
hand-held IMS units has been reported in military appli-
cations [160]. IMS has been used to identify some
metabolites [161] and bacteria in human breath [162].
Unfortunately, IMS cannot identify unknown volatile
compounds in a sample [161, 163].
4.6 Optical Absorption
Optical absorption can be employed to identify a disease
once a specific molecule associated with the disease has
been recognized. This method is very selective and can be
used to perform on-line real-time analysis of a specific
compound at the ppb level [7]. Chemiluminescence ana-
lyzers employed for measuring fractional concentrations of
exhaled nitric oxide (FeNO analyzers) work on the prin-
ciple of optical absorption. Such instruments are charac-
terized by their high cost, large size, and poor portability.
However, low-cost portable instruments based on the
electrochemical cell technique have been recently devel-
oped [164].
Table 3 gives a brief summary of the applications,
advantages, and disadvantages of analytical methods used
in breath testing.
5 Diabetes Mellitus and Breath Test
5.1 Diabetes
Diabetes mellitus, one of the major diseases, poses a great
threat to human health and has become a universal epi-
demic [165–167]. According to the World Health Organi-
zation (WHO), approximately 350 million people globally
have diabetes, which is projected to be the 7th leading
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cause of death in the year 2030 [166, 168, 169]. Diabetes
also refers to a variable and complicated disease condition
that can severely affect almost every organ in the human
body. This disease may be considered as a combination of
several diseases with versatile origins, various ages of
onset, and multiple treatment requirements [167].
Diabetes manifests itself as an uncommon combina-
tion of dramatic symptoms and has a lethal outcome
[170]. It is a common metabolic disorder characterized
by chronic hyperglycemia that can be potentially life-
threatening. Improper management of this deadly disease
may lead to damage of the eyes, kidneys, heart, and
nerves [166, 171].
5.2 Classification of Diabetes
WHO classifies diabetes into type 1 diabetes (insulin-de-
pendent diabetes mellitus) and type 2 diabetes (non-in-
sulin-dependent diabetes mellitus). Type 1 diabetes stems
from an absolute insulin deficiency. Usually, it is an
autoimmune disease and can lead to the destruction of the
insulin-secreting beta cells in the pancreas. However, the
origin of the destruction of beta cells is unknown in some
cases. Type 2 diabetes results from a relative insulin defi-
ciency that may be associated with varying degrees of
insulin action defects, known collectively as insulin resis-
tance [167]. It spreads in the body much more slowly than
does type 1 and does not make people sick as fast. When it
victimizes people, it can appear to be formidable one
[116, 117].
Diabetes mellitus can appear in forms other than type 1
and type 2. It can also originate from gene mutations,
pancreatic damage, and excessive hormone production.
Diabetes can also be induced by medications. For example,
Niacin is used to lower triglyceride levels and raise HDL
cholesterol levels. Niacin lowers insulin effectiveness and
can cause an increase in blood glucose levels (BGLs)
[172]. Gestational diabetes mellitus (GDM) is another form
of diabetes [172, 173]. It can develop when a pregnant
woman has limited beta cell capacity and cannot respond to
the additional insulin demand. An oral glucose tolerance
test is the general approach for GDM screening. A recent
study used breath gas analysis using PTR-MS for screening
GDM [173].
6 Breath Analysis for Diabetes Mellitus
and Available Techniques
The management of any disease requires its timely and
regular diagnosis. The traditional method for diagnosing or
monitoring diabetes is collecting blood samples from
patients to check whether their BGL falls within the normal
range. This method is accurate but painful, invasive,
inconvenient, and impractical and may be expensive
[12, 174–176].
In addition, the measurement of plasma insulin has
clinical importance for monitoring the progression of type
2 diabetes, discriminating common states (where compo-
nents of both type 1 and type 2 diabetes are present
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simultaneously), and assessing and screening prediabetic
states [174, 176]. Also, monitoring insulin is helpful in
investigating aspects of metabolism. Insulin regulates
glucose disposal and also exerts a strong antilipolytic effect
that is reduced significantly in patients with insulin resis-
tance [174, 177]. However, tests for insulin concentration
and sensitivity are very laborious. Tests for circulating
lipids are important for diabetic patients as hyperlipidemia
is a critical risk factor for heart disease. As lipids enhance
ketone body formation, any change in their levels may also
be related to changes in insulin or glucose metabolism
[174, 178]. Detailed knowledge and information of the
interplay of these metabolic variables and their pathways
may give clinical professionals insight into their patients’
health and hygiene, and reliable noninvasive monitoring,
which would improve both the diagnosis and treatment of
diabetes.
Researchers have thus focused on noninvasive methods
for screening diabetes and predicting BGL. Such methods
include bioimpedance spectroscopy, fluorescence technol-
ogy, and iontophoresis [179, 180]. However, these methods
suffer from a lack of specificity and inaccuracy due to
subject movement and sweating, skin irritation, etc.
[165, 179, 180]. Despite the number of studies carried out,
no FDA-approved commercial device for screening dia-
betes and predicting BGL exists [181].
An emerging and promising noninvasive approach for
diagnosing diabetes is the breath test. Exhaled breath con-
sists of a large number of various gaseous VOCs. These
VOCs may be used as noninvasive biomarkers of a number
of diseases, including diabetes. It has been reported that
concentrations of several breath biomarkers in diabetics
show significant differences from those for normal healthy
subjects. Also, the concentrations of some biomarkers are
correlated with the BGLs of diabetics. Thus, it is possible
both to screen diabetes and predict BGLs by analyzing the
exhaled breath VOCs or breath biomarkers of diabetes
patients. For clinical applications, breath analysis is a non-
invasive approach. Analysis of breath biomarkers and their
concentrations has great potential for detecting a disease,
monitoring its progression, or monitoring therapy [165, 182].
Several investigations have been carried out to study the
breath biomarkers of diabetes. Acetone and other VOCs
[165, 183–187] in breath have been shown either to have
abnormal concentrations in diabetics compared to healthy
controls or to correlate with the BGL. Compared to other
noninvasive approaches for diabetes management, breath
analysis is more advantageous and readily acceptable and it
is easier to collect samples for it [174], making it an
attractive and effective method for noninvasive diabetes
screening and BGL prediction [174, 175].
7 Physiological Aspects of Diabetes Mellitus
Related to Breath Test
The diagnosis, screening, or monitoring of a disease using
the breath test is not a simple task. Implementation of
breath test for detecting a disease and accurate interpreta-
tion of the measured data not only require details of the
pathophysiological background and systemic metabolism
underlying the particular disease condition of the subject
but also an elaborate understanding of the same under
normal healthy conditions. Additionally, the methodology
and technology used for such a test affect conclusions
regarding the disease. Characterization, interpretation,
quantification, and analysis of VOCs found in breath for a
diseased subject are of great importance as those of for a
healthy person for a significant statistical interpretation of
the obtained data.
An accurate breath test for diabetes mellitus needs the
proper realization of the changes of pathophysiological
mechanisms and systemic metabolism induced by the dis-
ease. Such changes may be useful for the diagnosis of
diabetes [174]. The following discussion highlights the
changes in the lungs and systemic metabolism in diabetics.
7.1 Lungs
It is believed that both the pulmonary vasculature and lung
function are affected by diabetes, which deteriorates the
gas exchange kinetics of several VOCs. This should be
taken into consideration when incorporating VOCs in the
breath test for diabetes. Further progress of the disease
imparts severe pathological changes, which would require
frequent recalibration or prevent specific VOCs from being
used in the breath test. It should be noted here that although
the underlying pathophysiological mechanisms are not
fully understood, several studies have investigated such
mechanisms in diabetics.
It has been reported that there is a correlation between
diabetes (both types) and mild restrictive lung disease and
micropathology-induced declined diffusion capacity. Such
micropathology originates from non-enzymatic glycation
and results in stiffening of the lung tissues [174, 188].
Thicker epithelial and endothelial capillary basal laminae
have been found in diabetes patients after autopsies
[174, 189]. Diabetic subjects also manifest elevated levels
of plasma myeloperoxidase (which produces damaging
oxidative species) and a-defensins (which promote
atherosclerosis and lung injury) [155, 174, 190–192] and
have increased risk of ROS production, pulmonary hyper-
tension (type 2 patients), and enhanced pro-sclerotic and
pro-fibrotic growth factors [174, 193, 194].
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7.2 Systemic Metabolism
The breath composition of diabetic subjects is changed due
to the metabolic activities involved with the disease.
Altered BGLs affect the breath VOC concentrations. Glu-
cose may also indirectly affect other VOC levels. This can
be exemplified by a variation in the rate of acetone for-
mation due to hyperglycemia, induced by the associated
suppressive effect of physiological compensatory hyper-
insulinemia, which at its elevated stage characterizes type 2
diabetes and suppresses lipolysis [174, 177]. Exhaled
breath isoprene also changes due to alteration in cholesterol
biosynthesis [74, 174]. Thus, the variation in concentra-
tions of ketones and other VOCs may be manifestations of
the changing metabolism of glucose and insulin.
8 Relating Breath VOCs to Diabetes Mellitus
Several studies have been carried out to investigate exhaled
breath VOCs related to diabetes mellitus. Breath analysis
of diabetic subjects can provide information about their
BGLs. Exhaled acetone has been reported to be an
important biomarker of diabetes [195]. Since the 1960s, a
Table 4 VOCs found in breath of diabetes patients and healthy normal subjects
Sl. no. VOC Type of
diabetes
Applied method Concentration (ppb) (range/median/mean)a
Normal healthy subjects Diabetes mellitus
patients












44 [199] to 2744 [83] 2200 [200] to 21000
[165, 201] (type 1)
1760 [165, 183] to
9400 [200] (type
2)
2 Ethylbenzene [174, 214] Type 1 Gas chromatography [214] 0.28 [208] to 18.38 [199] NA
3 Xylene [174, 223] Type 2 Solid-phase micro extraction
GC–MS analysis [223]
0.54–1.43 [208] NA
4 Toluene [174, 223] Type 2 Solid-phase micro extraction
GC–MS analysis [223]
1.45–37.21 [199] NA
5 Ethane [174, 227] Type 1
and 2
GC–MS analysis [227] 0.51–1.02 [216] NA






7 Propane [174, 214] Type 1 Gas chromatography [214] 3.71–19.98 [212] NA
8 Isoprene [174] Type 2 GC–MS analysis [212] 12.71 [209] to 227 [210] NA
9 Ethanol [174, 214] Type 1 Gas chromatography [214] 27 [217] to 216.1 [218] NA
10 Methanol [174, 214] Type 1 Gas chromatography [214] 33.05–216.1 [218] NA
11 Isopropanol [223] Type 2 Solid-phase micro extraction
GC–MS analysis [223]
3.21 [199] to 94.1 [13] NA
12 2,3,4-Trimethylhexane
[223]





Type 2 Solid-phase micro extraction
GC–MS analysis [223]
NA NA
14 Tridecane [223] Type 2 Solid-phase micro extraction
GC–MS analysis [223]
NA NA
15 Undecane [223] Type 2 Solid-phase micro extraction
GC–MS analysis [223]
0–4.83 [219] NA
NA not available in the literature
a Data in other units (e.g., nmol/l, lg/l, etc.) are converted to equivalent ppb unit, considering breath temperature at 310 K and following the
conversation formula applied in Ref. [212]
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large number of studies have been conducted on the anal-
ysis of acetone in the expired breath of diabetics
[195–197]. Breath acetone is linked to ketoacidosis
[174, 198]. Elevated levels of acetone in the blood and
breath of diabetics are a key cause of the fruity or sweet
smell of the subjects’ expired breath [195]. Studies have
also found a high correlation between BGL and the con-
centration of breath acetone [165, 185, 186, 195, 197, 198]
in patients with diabetes. The exhaled breath acetone
concentration has been reported to be in the range of
0.044 ppm [199] to 2.744 ppm [83] for normal healthy
subjects, 2.2 ppm [200] to 21 ppm [165, 201] for type 1
diabetes patients, and 1.76 ppm [165, 183] to 9.4 ppm
[200] for type 2 diabetes patients. The elevation of acetone
level indicates either a deficit of insulin in cells or cells’
inability to effectively utilize available insulin [28]. Breath
acetone can thus serve as a potential noninvasive bio-
marker of diabetes [28, 195].
However, the determination of breath acetone con-
centration alone may not optimize the diagnosis of dia-
betes as this concentration is also affected by the degree
of insulin resistance, diurnal fluctuations, lipolytic activ-
ity, diet nutrient composition, gender [174], body exercise
[28], and fasting status [28, 174]. Studies have shown the
presence of other breath VOCs in the diabetics’ breath. A
correlation between breath ethanol and BGL was reported
by Galassetti et al. [195, 198]. Experiments on animals
have also yielded interesting results. An elevated acetone
level was found in obese mice after the application of a
high-fat diet even after fasting [202]. Alteration in exha-
lation pattern and volatile metabolites was found during
fasting and low-dose glucose treatment [203]. Hyper-
glycemia may influence medullary thyrotropin-releasing
hormone stimulation of vagal outflow to the stomach
[204].
Table 4 lists VOCs found in the exhaled breath of dia-
betes patients and normal healthy subjects. Few studies
have reported the concentration ranges of breath VOCs,
except for acetone, for diabetes mellitus patients.
9 Conclusion
This review paper reflects the research trends and devel-
opments of breath analysis in disease determination since
1966. The status of characteristic breath VOCs (mostly of
systemic origin) at various physiological states was dis-
cussed. The advantages and limitations of breath tests and
related analytical methods were highlighted. The applica-
tion of breath VOC analysis to the diagnosis of diabetes
mellitus was reviewed. 15 VOCs found in diabetics’ breath
were listed, along with a list of 50 VOCs and their con-
centration ranges for normal healthy persons. The
concentration ranges of a few breath VOCs found in dis-
ease conditions (e.g., lung cancer) were also highlighted.
Despite the potential of breath tests for the clinical
diagnosis of several diseases, such tests have some draw-
backs. The major challenge limiting the application of breath
analysis in the clinical domain is the lack of standardization
in both breath collection [4, 5, 205] and analytical approa-
ches [4, 205, 206], which contribute to the wide variations of
reported analytical results [5, 99, 182, 207]. Additionally,
insight into the metabolic aspects and background physiol-
ogy of breath VOCs and their exact contributions both to
healthy and diseased states is required to justify their clinical
importance from a diagnostic point of view. Breath tests are
currently rarely used in clinical practice. However, it is
expected that ongoing research and development in medical
science and sensor-based analytical instrumentation in
breathomics will establish breath analysis as a reliable
approach for the detection and monitoring of various
diseases.
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